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Abstract
One year after the revelation by Dr. Furchgott in 1980 that the endothelium was obligatory for
acetylcholine to relax isolated arteries, it was clearly shown that the endothelium could also
promote contraction. In 1988, Dr. Yanagisawa’s group identified endothelin-1 (ET-1) as the first
endothelium-derived contracting factor. The circulating levels of this short (21-amino acid)
peptide were quickly determined in humans, and it was reported that, in most cardiovascular
diseases, circulating levels of ET-1 were increased, and ET-1 was then tagged as “a bad guy.” The
discovery of two receptor subtypes in 1990, ETA and ETB, permitted optimization of the first dual
ET-1 receptor antagonist in 1993 by Dr. Clozel’s team, who entered clinical development with
bosentan, which was offered to patients with pulmonary arterial hypertension in 2001. The
revelation of Dr. Furchgott opened a Pandora’s box with ET-1 as one of the actors. In this brief
review, we will discuss the physiological and pathophysiological role of endothelium-derived
ET-1 focusing on the regulation of the vascular tone, and as much as possible in humans. The
coronary bed will be used as a running example in this review because it is the most susceptible to
endothelial dysfunction, but references to the cerebral and renal circulation will also be made.
Many of the cardiovascular complications associated with aging and cardiovascular risk factors
are initially attributable, at least in part, to endothelial dysfunction, particularly dysregulation of
the vascular function associated with an imbalance in the close interdependence of nitric oxide and
ET-1.
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Introduction
Dr. Furchgott rediscovered an extraordinary organ, the endothelium, that protects the arterial
wall through the release of nitric oxide (NO) [1, 2] among other factors. Before 1980, the
endothelium was merely considered as an anticoagulant sheet of cellophane. The presence of
an endothelium-derived constricting factor (EDCF) was perceived 1 year after the revelation
of the endothelium-dependent relaxant properties of the endothelium [3, 4]. But, it was 8
years later that Yanagisawa and colleagues identified an EDCF, endothelin-1 (ET-1) [5, 6].
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Two receptors for ET-1 were identified 2 years later [7, 8]. Then, shortly after the discovery
of ETA and ETB receptors, Martine Clozel’s team presented in 1993 the first orally active
endothelin-1 receptor antagonist, Ro 46-2005 [9], and the same team made a structurally
modified analog, bosentan (Tracleer), available to patients with pulmonary arterial
hypertension at the end of 2001. In less than 15 years, a new factor was identified, its
receptors were cloned, and their pharmacology was characterized, a pathology associated
with the abnormal function of the ET-1 system and an effective treatment offered to patients
in need. It all started from the “so-obvious-today” rediscovery of the endothelial cells by Dr.
Furchgott.
In this short review, we will focus on ET-1 and the endothelium and thus, review the role of
ET-1 on the vasculature with as much as possible references to the human pathophysiology.
Physiological effects of ET-1 in arteries
Endothelin-1 is one of the most potent endogenous vasoconstrictor identified so far [6]. This
peptide induces a long-lasting contraction of isolated porcine coronary arteries with a half
maximum effective concentration (EC50) of 0.4± 0.2 nM, which is at least one order of
magnitude lower than values reported for other contracting peptides such as angiotensin II,
with the exception of urotensin II [10]. In contrast to urotensin II, however, ET-1 induces
contraction of almost all arteries and veins tested. There are two additional isoforms of
endothelins, ET-2 and ET-3. Among these, ET-1 is the prominent isoform synthesized by
the vasculature [6].
ET-1 is released continuously, mostly from endothelial cells (EC), by a constitutive and
regulated pathway [11] and contributes to the maintenance of vascular tone [12–15]. NO
strongly inhibits the release of ET-1 from the native endothelium [16, 17], which makes
ET-1 and NO functionally closely interdependent, with a strong inhibitory effect of ET-1 on
NO-mediated dilation, including in human coronary and cerebral arteries, and vice versa
[14, 18–21]. The inhibitory effects of ET-1 are not limited to the dilations induced by NO
since ET-1, through activation of the protein kinase C pathway, also reduces β-adrenergic
receptor-dependent relaxation both in vitro and in vivo [22, 23]. This peptide is therefore a
potent “anti-vasodilatory” factor released by the endothelium.
In addition to its genesis by EC, ET-1 is produced by vascular smooth muscle cells (VSMC),
cardiomyocytes, leukocytes, macrophages, various neurons, and other cells [24]. ET-1 is not
only a potent vasoconstrictor, but at elevated concentrations—pharmacological and
pathological—it is also proinflammatory and promotes VSMC proliferation [25–30]. These
latter properties of ET-1 are important in pulmonary arterial hypertension and probably
other vascular diseases such as atherosclerosis and venous graft occlusion as we will see
later. In the physiological environment, ET-1 certainly contributes to cardiovascular
homeostasis through several pathways that impact on the regulation of basal vascular tone
[12, 24] (Fig. 1).
The production of ET-1 is regulated at the gene level [31]: ET-1 messenger RNA (mRNA)
is upregulated by inflammatory factors such as transforming growth factor beta, tumor
necrosis factor alpha, interleukins, insulin, and angiotensin II, and downregulated by NO,
PGI2, hypoxia, and shear stress [12, 24]. It is synthesized as a large protein, the pre-proET-1
or Big ET-1 that is cleaved first to pro-ET-1 and second to ET-1 by ET-converting enzymes
(ECE-1 and ECE-2), but additional peptidases can generate ET-1 as demonstrated by
experiments in ECE1/2 knockout mice [32]. The biological effects of ET-1 are mediated
through activation of the two known ET-1 receptors, ETA and ETB [7, 8]. Although both
receptors are important for normal function, the debate in the literature is whether or not
both receptors should be blocked to provide most clinical benefit [33, 34]. The ETA has
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been classified as the bad one, while the ETB is considered as the good one; this distinction
is based on the role of ETB in the clearance of circulating ET-1 and on the observation that
activation of endothelial ETB induces dilatation by stimulating the release of endothelial
prostacyclin and NO. Inhibition of ETB increases circulating ET-1 levels and blood pressure
in healthy subjects [35] demonstrating that ETB stimulation is overall vasodilatory. This
debate will not be closed unless we learn more on the pathophysiology of ET-1.
Vascular effects of ET-1
In this section, we will mostly, but not exclusively, report data collected in the coronary
arteries since excellent reviews have been recently published on the pulmonary vascular bed
[36, 37]. The coronary vascular bed is unique because in this vascular territory shear stress,
the tangential force per unit area created by flow of blood over the luminal surface of the
endothelium is the most unstable. The vascular endothelium-dependent dilation to shear
stress permits fine tuning of nutrient delivery to accommodate metabolic demand [38, 39],
and the stability of shear stress, rather than its level, contributes to the maintenance of a
healthy endothelium [39]. In coronary arteries, blood flow varies throughout the cardiac
cycle [40]: blood flows in the coronary arteries during diastole and reverses during systole
as the contracting myocardium squeezes the subendocardial coronary arteries. Mechanical
stress is nowhere else more pronounced in the circulation. In turn, the coronary circulation is
the prime site for endothelial dysfunction. Because of these unique physiological
hemodynamic features, coronary arteries display an unusual gene pattern when compared to
the aorta: a fivefold lower endothelial NO synthase and a 2.5-fold higher ET-1 mRNA
expressions [41]. Based on our current knowledge, this pattern would predispose to
endothelial dysfunction and atherosclerosis and is directly in line with the functional
interaction existing between NO and ET-1, in favor of ET-1.
Systemic exogenous administration of ET-1 induces a biphasic response, an initial and
transient reduction in blood pressure followed by a sustained hypertensive phase. The
depressor phase involves endothelial ETB receptors whereas the hypertensive phase is
mediated by ETA receptors [42]. Similarly, isolated rat hearts perfused with exogenous ET-1
display a biphasic response: a drop in coronary perfusion pressure associated with coronary
dilation was observed at low concentrations of ET-1, while a rise in coronary perfusion
pressure associated with a coronary constriction was observed at high concentrations of
ET-1 [12]. In addition, the effect of exogenous ET-1 on the coronary circulation may vary
according to the mode of administration (bolus, infusions) and the experimental conditions
(conscious versus anesthetized) [43]. It has been reported that, in coronary arteries, ETA are
far more dominant in VSMC than ETB, and thus that ET-1 acts mainly as a vasoconstrictor
[44].
The contribution of endogenously generated ET-1 to the coronary vessel tone in humans was
assessed in patients undergoing routine diagnostic cardiac catheterization for suspected
coronary artery disease (CAD), by intracoronary infusion of BQ123 (100 nmol/min, for 60
min), a selective antagonist of ETA receptors [45]. Inhibition of ETA receptors caused a
coronary dilation in proximal and distal segments, an increase in coronary blood flow, and a
decrease in coronary resistance. This result was confirmed by Ganz’s group showing that
BQ123 (40 nmol/min, for 60 min) increased coronary artery diameter by 7% compared to
21% with nitroglycerine [46]. In this study, ET-1 was estimated to contribute to 39% of total
vasomotor tone in healthy subjects. Similarly, MacCarthy et al. reported that intracoronary
infusion of BQ123 (40 nmol/min, for 15 min) in patients with angiographically normal
coronary arteries induced a reversible dilation of proximal, mid, and distal vessels, an
increase in coronary blood flow, but no changes in systemic hemodynamic [47]. The
vasodilatory effect of BQ123 appeared greater in distal vessels, likely explicable by the
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distribution of ETA in human coronary arteries. BQ123 highlights the importance in ETA-
mediated contraction in coronary arteries, but also unmasks the role of endothelial ETB-
dependent dilation mediated by NO and prostacyclin release [13, 15].
ET-1 not only exerts direct constrictor effects, but is also able, at low concentrations, to
potentiate contractile responses to other vasoconstrictor substances such as norepinephrine
and serotonin; on the other hand, the presence of small concentrations of vasoconstrictor
substances can amplify the response to ET-1 [15, 48]. In isolated human cerebral arteries,
endothelium-derived ET-1 augmented significantly serotonin-induced contraction, and
BQ-123 prevented the rise in tone induced by inhibition of NO production [49]. Thus, even
subthreshold concentrations of ET-1 may regulate vascular tone and reactivity. This is likely
the physiological function of ET-1.
The role of ETB beside clearance of ET-1 and its endothelium-dependent dilatory activity is
poorly understood. This is complicated by the possible change in expression of ET-1
receptors during the development of pathologies as evidenced in pulmonary hypertension
[50] and renal diseases [51, 52] or by chronically doubling the circulating levels of ET-1
[53]. For example, doubling the circulating levels of ET-1 in dogs induces, likely under the
control of ETB receptors, a reduction in cardiac output and heart rate combined with an
increased systemic and renal vascular resistance and an antinatriuretic effect [54]. In
addition, it has been reported that ETB receptors may play a role in the potentiation of the
contraction induced by neurohormones such as angiotensin II and norepinephrine by low
doses of ET-1 [55].
In summary, the endogenous ET-1-dependent control of tone in normal arteries depends on
the balance between ETA- and ETB-mediated effects and on factors such as receptor
distribution and endothelial integrity.
Physiological control of vascular remodeling
It has been reported that ET-1 modulates the expression of extracellular matrix (ECM) and
matrix metalloproteinases, the main enzymes that degrade ECM molecules [56]. This
confers to ET-1 a role in vascular remodeling. Vessel remodeling, however, should be
considered as an adaptive response and is usually associated with endothelial dysfunction
and vascular disease. ET-1, via ETA, mediates intimal hyperplasia in human saphenous vein
graft [26, 27]. Similarly, when compared to control healthy internal mammary artery
segments, segments isolated from patients with CAD displayed increased in situ
immunostaining to ET-1 and ETA/ETB in VSMC, increased total and type 1 collagen, and a
higher rate of VSMC proliferation, suggesting that ET-1 plays a role in arterial remodeling
associated with CAD [57]. Recently, it has been reported that, in vascular endothelial cell
ET-1 knockout mice, neointima formation induced by arterial (carotid) ligation was reduced,
SMC proliferation decreased, and expression of endothelial adhesion molecules was
inhibited [25]. This is a direct evidence for the role of endothelial ET-1 in mediating
neointima formation following vascular injury. Hence, beyond its known vasoconstrictor
effects, ET-1 is an important mediator of vascular remodeling. The links between ET-1-
induced signaling events and the vascular remodeling are largely unknown, since the role of
ET-1 in remodeling has been evidenced under stress conditions only.
ET-1 stimulates angiogenesis
Another mean by which ET-1 may be beneficial to tissue perfusion is through its ability to
stimulate angiogenesis. Angiogenesis is the final common pathway in ischemia-induced
neovascularization as well as formation of collateral vessels in cardiovascular diseases. Both
in vitro experiments using isolated endothelial cells and in vivo models showed that ET-1
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induces angiogenesis via ETB [58, 59]. Tissue hypoxia is a physiological stimulus for
angiogenesis, and ET-1 production is also enhanced by hypoxia. In cardiomyocytes, ET-1
triggers connective tissue growth factor, a fibrotic mediator that regulates cell proliferation,
migration, and ECM accumulation and thus plays a role in angiogenesis and tissue repair
[60]. The angiogenic property of ET-1 could potentially be involved in the
neovascularization described in atherosclerotic human coronary arteries.
In summary, the physiological roles of ET-1 involve maintenance of normal blood vessel
tone, cellular proliferation, tissue development and repair, and angiogenesis.
Pathophysiological vascular effects of ET-1
The rise in circulating ET-1 levels
Under normal physiological conditions, the plasmatic concentration of ET-1 is around 1 pM,
but it has been reported that the local concentration of ET-1 within the vascular wall is 100-
fold higher than that of plasma levels [24]. The changes in plasmatic concentration of ET-1
may therefore not directly reflect changes in ET-1 release/clearance/breakdown associated
with pathological conditions. Nonetheless, it has been shown that doubling circulating ET-1
levels acutely in dogs decreased heart rate and cardiac output without affecting blood
pressure, and therefore increasing systemic vascular resistance [54]. This experimental
increase in ET-1 was also associated with a rise in renal vascular resistance in association
with a decreased glomerular filtration rate, without affecting coronary flow and pulmonary
wedge pressure. On the other hand, doubling circulating levels of ET-1 chronically (7 days)
in rats increased systolic blood pressure [53]. Futhermore, α2-adrenergic receptor-dependent
contraction of isolated mesenteric arteries was increased, blunted by dual ETA/B inhibition
but not by selective ETA inhibition with BQ123. Therefore, chronic elevation of ET-1 leads
to changes in vascular reactivity possibly by affecting ETB-dependent responses.
Circulating levels of ET-1 have been reported to be elevated in patients with CAD and
atherosclerosis, pulmonary hypertension, diabetes [29, 30, 34, 61–64], in patients with
hypertension associated with renal failure [24], and in patients with heart failure [13, 65–
68]. Many of the cardiovascular complications associated with aging and cardiovascular risk
factors are attributable, at least in part, to endothelial dysfunction, particularly dysregulation
of the vascular tone induced by an imbalance between NO and ET-1. Therefore, the known
reduction of NO bioavailability in association with risk factors for cardiovascular diseases
and disease states could also explain the rise in ET-1. Subsequently, ET-1 may feed forward
by stimulating the production of damaging reactive oxygen species (ROS) [69] and hasten
the decline in endothelial function [39]; on the one hand, prevention of NO production
increases ET-1 release [16], while on the other hand, blockade of ET-1 receptors improves
NO-dependent, flow-mediated dilation in patients with CAD [61]. The chronic rise in ET-1
may then lead to a molecular remodeling of the endothelin system (receptors, enzyme,
associated proteins, etc.) and affect the cardiovascular system. By opposition, chronic
blockade of ETA (4 weeks) in rats with congestive heart failure partially restored guanylate
cyclase sensitivity and the loss of endothelial cell/smooth muscle cell communication [70].
Therefore, changes in ET-1 levels or blockade of its receptors have functional consequences
involving proteins and pathways outside of the endothelin system itself.
Coronary arterial vasospasm
The evidence that ET-1 plasma levels are elevated in the coronary circulation of patients
during angina, that ET-1 induces a long-lasting contraction in coronary arteries, and that
subthreshold concentrations of ET-1 potentiate the coronary constrictor effects of other
vasoconstrictors make ET-1 an ideal candidate for the initiation and the maintenance of
coronary arterial spasm [15]. This hypothesis has been validated recently in a case report
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[71]. In this report, a 46-year-old patient with severe and treatment-resistant coronary vaso-
spasm was treated successfully with the endothelin receptor antagonist bosentan. In acute
coronary syndrome, it was reported that the concentration of ET-1 in the thrombus exceeded
280 times that of angiotensin II, norepinephrine, and serotonin [72]. Importantly, thrombus
homogenates exerted vasoconstrictions of isolated porcine coronary artery rings that were
inhibited by the dual ET-1 receptor antagonist tezosentan. The recent demonstration that
following coronary artery endothelial dysfunction ET-1 is essential for a ROS-dependent
coronary vasospasm [69], a mechanism that could also be involved in coronary spasm
postcardiac transplantation [73], provides a strong rationale for testing ETA/B antagonists in
spastic angina.
Endothelial dysfunction and atherosclerosis
In 1995, it was shown that treatment of cholesterol-fed hamsters with the selective ETA
receptor antagonist BMS-182874 decreased the area of the fatty streak by reducing the
number and size of macrophage foam cells [74], strongly suggesting a proinflammatory role
of ETA activation. Lüscher’s group demonstrated that ETA inhibition improved endothelial
dysfunction and reduced atherosclerosis development in ApoE knockout mice [75]. In pigs
fed with a high-cholesterol diet, both selective ETA and dual ETA/B chronic treatment
selectively increased coronary blood flow induced by intracoronary infusion of
acetylcholine [76], while following myocardial infarction in rats, treatment with both the
selective ETA antagonist LU 135252 and the dual ETA/B antagonist bosentan improved
acetylcholine-induced relaxation [77]. Several studies have reported the effects of
intracoronary infusion of the ETA antagonist BQ123 on coronary diameter and coronary
flow in patients with CAD. As in healthy patients, Dr. Webb’s group showed that BQ123
(100 nmol/min, for 60 min) increased diameter and coronary flow [45]. In contrast, Ganz’s
group reported that BQ123 (40 nmol/min, for 60 min) increased more coronary artery
diameter in patients with CAD than without [46]. In this latter study, compared with the
dilation to nitroglycerin, ET-1 contributed to 39% of coronary vasomotor tone in healthy
subjects, 74% of tone in CAD arteries, and 106% of tone at stenoses. The contribution of
NO, that is the endothelial dilatory function, was, however, not determined: one would
assume that the more severe the diseases state the less NO would be produced (if any), and
the more ET-1 would contribute to tone. This hypothesis was tested in 44 patients with CAD
in a study published that same year in 2001: Halcox et al. provided the first evidence that
ET-1, via ETA, contributed to reduce the endothelial dilatory function [63]. Intracoronary
infusion of BQ123 (200 nmol/min, for 1 h) in patients with atherosclerosis resulted in
coronary artery dilation and an improvement of acetylcholine-induced endothelium-
dependent dilation. The patients with the greatest endothelial dysfunction benefited the most
from the intracoronary infusion of the ETA antagonist [63]. In pig coronary arteries
subjected to ischemia reperfusion, another model of endothelial dysfunction, the
vasoreactivity to exogenous ET-1 was increased and associated with a reduction in
endothelial ETB-mediated dilation and an increase in vascular smooth muscle ETB-
dependent contraction [78]. Bohm et al. reported that both selective ETA (BQ123) and the
combination of selective ETA (BQ123) and ETB (BQ788) antagonists improved endothelial-
dependent dilation in coronary arteries from patients with CAD [61]. Again, the dilation was
higher in severely stenotic segments, demonstrating that the importance of ET-1 in the
control of vascular tone is increased in atherosclerosis. In agreement with these data, using
isolated human coronary arteries from idiopathic and atherosclerotic cardiomyopathic
hearts, we demonstrated that ET-1-dependent constriction became more important when
endothelial function was altered [21]. Taken together, these data strongly suggest that ET-1
is an important contributor to endothelial dysfunction in the coronary arterial bed. The role
of the ETB needs also to be considered because its expression increases in experimental
hypercholesterolemia, promoting contraction of isolated pig coronary arterial rings at low
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concentrations (0.1 nM) of ET-1 and sarafotoxin-6c, a selective ETB agonist [79]. Hence,
the functional contribution of ET-1 appears to rise with the severity of the disease. Raised
plasma levels of ET-1 have been reported in patients with atherosclerosis, and upregulation
of ET-1 and its receptors has been described in atherosclerotic arteries and plaques [64, 67,
80, 81]. Big ET-1 and ET-1 immunoreactivity has been found in regions of atherosclerosis
[79, 82]. The constrictor, proinflammatory, chemoattractant, and mitogenic properties of
ET-1 also clearly support a role for ET-1 in the pathogenesis of atherosclerosis [29, 83].
Additional studies brought another perspective on the potential clinical development of ET-1
receptor antagonists based on the interactions between ET-1 and angiotensin II. ET-1
receptor inhibition combined with angiotensin-converting enzyme (ACE) inhibitors has been
shown to improve renal hemodynamics and sodium excretion in patients with chronic
kidney diseases [84, 85]. Most interestingly, dual ETA/B antagonism improved endothelium-
dependent dilation in the forearm in atherosclerotic patients treated with an ACE inhibitor
[86]. Similarly, ETA antagonism and ACE inhibition were efficient at preventing diabetic
renal lesions induced by diabetes in rats [51], and a recent study in treatment resistant
hypertension [87] shows efficacy on blood pressure and proteinuria in patients already
treated with renin–angiotensin system blockers. Since endothelin antagonists do not produce
hyperkalemia, and there is tremendous unmet need in the field of chronic proteinuric
nephropathy, this seems to be a very attractive area for further clinical development. This
dual therapeutic approach may also be efficient in several other cardiovascular diseases
including CAD, peripheral vascular diseases, and diabetes.
Conclusion
Although there are now a number of cardiovascular indications for endothelin receptor
antagonists, and a number under consideration, the physiology of ET-1 needs more
understanding. ET-1 is essential for normal physiological function, and its well-known
interaction with NO should be sufficient to stimulate more research. More data may
stimulate clinical development of ET receptors antagonists in atherosclerosis and diabetes
among others [33, 34, 88]. The legacy of Dr. Furchgott is not an endothelium with a Janus
face but a cellular layer that finely regulates tone and maintains wall integrity with high
levels of control. Dysfunctions develop with age or prematurely with exposure to
cardiovascular risk factors, and the loss of NO probably unbalances the system favoring
ET-1-dependent pathogenesis.
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Fig. 1.
Multiple vascular properties of ET-1
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